Compare Peptides

Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.

Popular comparisons

Pramlintide

Symlin, Amylin Analog

FDA Approved
Metabolic

Semaglutide

Ozempic, Wegovy

FDA Approved
GLP-1 Agonist
Overview

A synthetic analog of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. Represents the amylin pathway that cagrilintide (investigational) also targets.

A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.

Mechanism of Action

Mimics the effects of amylin: slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety. These effects complement insulin therapy by reducing postprandial glucose spikes and caloric intake.

Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.

Common Uses
  • Type 1 diabetes (adjunct to insulin)
  • Type 2 diabetes (adjunct to insulin)
  • Postprandial glucose control
  • Modest weight loss
  • Weight management
  • Type 2 diabetes treatment
  • Blood sugar regulation
  • Cardiovascular risk reduction
Known Risks
  • Severe hypoglycemia (especially in type 1 diabetes — boxed warning)
  • Nausea (common, usually transient)
  • Headache
  • Anorexia
  • Requires careful insulin dose adjustment
  • Nausea and vomiting (common, usually transient)
  • Pancreatitis (rare but serious)
  • Gallbladder issues
  • Potential thyroid tumor risk (animal studies)
  • Muscle mass loss alongside fat loss
  • GI side effects (diarrhea, constipation)
Regulatory Status
FDA Approved

FDA-approved as Symlin (2005) for type 1 and type 2 diabetes as an adjunct to mealtime insulin. Requires insulin dose reduction to prevent hypoglycemia. Pen injector for self-administration.

FDA Approved

FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.

This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.